Development and Validation of UPLC-MS/MS Method for Determination of Enasidenib in Rat Plasma and Its Pharmacokinetic Application

Table 5

Pharmacokinetic parameters of enasidenib in rats after 10 mg/kg oral administration (n = 8).

Parameters	Enasidenib
t1/2 (h)	7.99 ± 3.29
Tmax (h)	1.57 ± 0.73
Cmax (ng/mL)	456.80 ± 124.29
AUC0⟶t (ng/mL·h)	4754.06 ± 1685.42
AUC0⟶∞ (ng/mL·h)	4929.53 ± 1947.91
Vz/F (L/kg)	24.91 ± 9.80
CLz/F (L/h)	2.34 ± 1.01
MRT0⟶t (h)	12.85 ± 1.50
MRT0⟶∞ (h)	12.88 ± 1.06

Abbreviations: t_1/2, half-life; T_max, time of peak concentration; MRT_(0⟶t), mean residence time of 0 ⟶ t time; MRT_(0⟶∞), mean residence time of 0-infinity time; C_max, peak concentration; AUC_(0⟶t), area under the curve of 0 ⟶ t time; AUC_(0⟶∞), area under the curve of 0 ⟶ infinity time; V_z/F, apparent volume of distribution; and CL_z/F, clearance.